Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder
Primary Purpose
Overactive Bladder
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Health education intervention (HEI)
Sponsored by
About this trial
This is an interventional treatment trial for Overactive Bladder focused on measuring Medication Persistence, Compliance, Health Education Intervention (HEI)
Eligibility Criteria
Inclusion Criteria:
- Female aged ≥ 18 years with OAB symptoms for ≥ 3 months
- The sum score of the OABSS ≥ 3 with the score of the question no.3 (urgency) ≥ 2
- The sum score of the OAB V8 ≥ 8
Exclusion Criteria:
- Any condition that would contraindication of anticholinergic treatment
- Symptomatic acute UTI during the run-in period
- Diagnosed or suspected interstitial cystitis
- Treatment with anticholinergic drugs within 12 months prior to Screening and persist over 3 months
- Treatment within the 14 days preceding Screening, or expected to initiate treatment during the study with any other treatment for overactive bladder.
- An indwelling catheter or practicing intermittent self-catheterization
- Pregnant or nursing women
Sites / Locations
- Bucheon St. Mary's Hospital, The Catholic University of Korea
- Bucheon Hospital, Soonchunhyang University College of Medicine
- Samsung Changwon Hospital, Sungkyunkwan University School of Medicine
- Daegu Catholic University College of Medicine
- Chungnam National University Hospital
- Chonnam National University Medical School
- Pusan National University Hospital
- Cheil General Hospital & Women's Healthcare Center, College of Medicine, Kwandong University
- Seoul National University Hospital
- Yonsei University College of Medicine
- Samsung Medical Center, Sungkyunkwan University School of Medicine
- Anam Hospital, College of Medicine, Korea University
- Asan Medical Center, Ulsan University College of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Health education intervention (HEI)
No intervention
Arm Description
Outcomes
Primary Outcome Measures
Difference in the % of patients maintaining persistence between no intervention and HEI group
Definition of "Maintaining Persistence"= a gap of ≤ 30 days between successive prescription fills
Secondary Outcome Measures
Difference in the % of patients maintaining persistence between no intervention and HEI group
Difference in the % of the patients with the compliance rate ≥ 80% between no intervention and HEI group
Calculation of Compliance (%)= (total no. of drug prescribed - no. of remained drug)/total no. of drug prescribed x 100
Difference in the compliance rate between no intervention and HEI group
Difference in changes in OAB symptoms between no intervention and HEI group
OABSS OAB-q short form questionnaire
Difference in the treatment satisfaction between no intervention and HEI group
Reasons for non-persistence
Definition of non-persistence = a gap of > 30 days between successive prescription fills
Examples
Insufficient clinical response
Adverse event
Satisfied with treatment response
Laboratory abnormality
Subject died
Protocol violation
Lost to F/U
Subject no longer willing to participate in study
Pregnancy
High patient out-pocket cost
Others (provide detailed reason)
Adverse events
Full Information
NCT ID
NCT01515722
First Posted
July 22, 2011
Last Updated
March 18, 2020
Sponsor
Samsung Medical Center
Collaborators
Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT01515722
Brief Title
Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder
Official Title
Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder : 6-month, Randomized, Open-label, Multi-center Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Samsung Medical Center
Collaborators
Pfizer
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Study Objectives: To explore the effectiveness of adjunctive intervention to enhance the medication compliance and persistence in patients with Overactive Bladder (OAB), thereby to improve treatment outcomes
Study Hypothesis: Health Education Intervention (HEI) can enhance the medication compliance and persistence, thereby can improve the treatment outcomes in conjunction with pharmacological therapy in OAB patients
Study Design: 6-month, randomized, open-label, multi-center trial at 13 university hospitals
Detailed Description
Treatment - Fesoterodine (Toviaz) 4 or 8mg
Interventions (2 arms)
- Arm 1: No intervention
Patients in this arm will not be given HEI in conjunction with pharmacotherapy (Toviaz) which was developed for this trial.
- Arm 2: Health education intervention (HEI)
HEI will be performed by trained study coordinators with the leaflet designed for this trial composed of 4 parts.
Part 1: Understanding OAB Physiology of bladder Definition, symptom and prevalence of OAB OAB in a treatable condition. There are many options that may help your symptoms. Lifestyle change Medications Bladder training Pelvic floor muscle exercise
Part 2: Behavioral/lifestyle modification Modification of dietary habits Limit bladder irritants- caffeine (coffee, tea, coke...), juice, chemical flavors, spicy food. etc. Altering fluid intake Weight management Learn how weight can affect their condition Stop smoking Constipation management
Part 3: Bladder training Timed voiding- Goal is urinating every 3 or 4 hours during the day without fear of wetting accidents.
Urgency suppression Pelvic muscle contraction, count backwards from 100 by 7seconds, etc Pelvic floor muscle exercise Contraction (fast and slow) and relax the muscle for a count of 3. Repeat the fast and slow contractions 10 - 15 times. Do those at least 3 times a day.
Part 4: Understanding antimuscarinics How the medicine works How to take it Tips that may help manage side effects- dry mouth, constipation Therapy expectations
HEI include 3-day voiding diary for self tracking method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder
Keywords
Medication Persistence, Compliance, Health Education Intervention (HEI)
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
692 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Health education intervention (HEI)
Arm Type
Experimental
Arm Title
No intervention
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
Health education intervention (HEI)
Intervention Description
<Part 1> Understanding OAB
<Part 2> Behavioral/lifestyle modification
<Part 3> Bladder training
<Part 4> Understanding antimuscarinics
Primary Outcome Measure Information:
Title
Difference in the % of patients maintaining persistence between no intervention and HEI group
Description
Definition of "Maintaining Persistence"= a gap of ≤ 30 days between successive prescription fills
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Difference in the % of patients maintaining persistence between no intervention and HEI group
Time Frame
1, 2 and 4 months
Title
Difference in the % of the patients with the compliance rate ≥ 80% between no intervention and HEI group
Description
Calculation of Compliance (%)= (total no. of drug prescribed - no. of remained drug)/total no. of drug prescribed x 100
Time Frame
1, 2, 4, and 6 months
Title
Difference in the compliance rate between no intervention and HEI group
Time Frame
1, 2, 4 and 6 months
Title
Difference in changes in OAB symptoms between no intervention and HEI group
Description
OABSS OAB-q short form questionnaire
Time Frame
1, 2, 4, and 6 months
Title
Difference in the treatment satisfaction between no intervention and HEI group
Time Frame
1, 2, 4, and 6 months
Title
Reasons for non-persistence
Description
Definition of non-persistence = a gap of > 30 days between successive prescription fills
Examples
Insufficient clinical response
Adverse event
Satisfied with treatment response
Laboratory abnormality
Subject died
Protocol violation
Lost to F/U
Subject no longer willing to participate in study
Pregnancy
High patient out-pocket cost
Others (provide detailed reason)
Time Frame
1, 2, 4, and 6 months
Title
Adverse events
Time Frame
1, 2, 4, and 6 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female aged ≥ 18 years with OAB symptoms for ≥ 3 months
The sum score of the OABSS ≥ 3 with the score of the question no.3 (urgency) ≥ 2
The sum score of the OAB V8 ≥ 8
Exclusion Criteria:
Any condition that would contraindication of anticholinergic treatment
Symptomatic acute UTI during the run-in period
Diagnosed or suspected interstitial cystitis
Treatment with anticholinergic drugs within 12 months prior to Screening and persist over 3 months
Treatment within the 14 days preceding Screening, or expected to initiate treatment during the study with any other treatment for overactive bladder.
An indwelling catheter or practicing intermittent self-catheterization
Pregnant or nursing women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyu-Sung Lee, MD, PhD
Organizational Affiliation
Samsung Medical Center, Sungkyunkwan University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bucheon St. Mary's Hospital, The Catholic University of Korea
City
Bucheon
ZIP/Postal Code
420-717
Country
Korea, Republic of
Facility Name
Bucheon Hospital, Soonchunhyang University College of Medicine
City
Bucheon
ZIP/Postal Code
420-767
Country
Korea, Republic of
Facility Name
Samsung Changwon Hospital, Sungkyunkwan University School of Medicine
City
Changwon
ZIP/Postal Code
630-522
Country
Korea, Republic of
Facility Name
Daegu Catholic University College of Medicine
City
Daegu
ZIP/Postal Code
705-034
Country
Korea, Republic of
Facility Name
Chungnam National University Hospital
City
Daejeon
ZIP/Postal Code
301-721
Country
Korea, Republic of
Facility Name
Chonnam National University Medical School
City
Gwangju
ZIP/Postal Code
501-757
Country
Korea, Republic of
Facility Name
Pusan National University Hospital
City
Pusan
ZIP/Postal Code
602-739
Country
Korea, Republic of
Facility Name
Cheil General Hospital & Women's Healthcare Center, College of Medicine, Kwandong University
City
Seoul
ZIP/Postal Code
100-380
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
Yonsei University College of Medicine
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Facility Name
Samsung Medical Center, Sungkyunkwan University School of Medicine
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
Facility Name
Anam Hospital, College of Medicine, Korea University
City
Seoul
ZIP/Postal Code
136-705
Country
Korea, Republic of
Facility Name
Asan Medical Center, Ulsan University College of Medicine
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder
We'll reach out to this number within 24 hrs